The Real-Life Efficacy and Safety of Telmisartan in Patients With Arterial Hypertension - Full Text View

Sponsor:	Bayer
Information provided by:	Bayer
ClinicalTrials.gov Identifier:	NCT00471003

Purpose

The main purpose of this study is to asses the efficacy and safety of telmisartan, with the special attention on the influence of telmisartan on selected metabolic parameters of patients.

Condition	Intervention
Hypertension	Drug: Pritor (Telmisartan , BAY68-9291)

Study Type:	Observational
Study Design:	Observational Model: Cohort Time Perspective: Prospective
Official Title:	A Non-Interventional, Post-Marketing Surveillance Phase IV Study to Asses the Efficacy and Safety of Telmisartan, With the Special Attention on the Influence of Telmisartan on Selected Metabolic Parameters of Patients

Resource links provided by NLM:

MedlinePlus related topics: High Blood Pressure

Drug Information available for: Telmisartan

U.S. FDA Resources

Further study details as provided by Bayer:

Primary Outcome Measures:

Efficacy and safety of the treatment with telmisartan reported by the physician [ Time Frame: At the both of planned control visits. (Approx. interval between visits 3 months) ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

Changes in metabolic parameters in telmisartan treated patients [ Time Frame: At the both of planned control visits. (Approx. interval between visits 3 months) ] [ Designated as safety issue: No ]

Enrollment:	5448
Study Start Date:	September 2006
Study Completion Date:	November 2009
Primary Completion Date:	November 2009 (Final data collection date for primary outcome measure)

Groups/Cohorts	Assigned Interventions
Arm 1	Drug: Pritor (Telmisartan , BAY68-9291) Primary care hypertensive patients starting the therapy with Telmisartan

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Primary care clinic

Criteria

Inclusion Criteria:

Age over 18
Untreated or ineffectively treated arterial hypertension

Exclusion Criteria:

Cholestatic disorders and severe hepatic failure
Allergy to telmisartan
Pregnancy and lactation period

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00471003

Locations

Croatia

Many Locations, Croatia
Poland

Many Locations, Poland
Slovakia

Many Locations, Slovakia
Slovenia

Many Locations, Slovenia

Sponsors and Collaborators

Bayer

Investigators

Study Director:

Bayer Study Director

Bayer

More Information

Additional Information:

Click here and search for drug information provided by the FDA This link exits the ClinicalTrials.gov site

Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party:	Medical Affairs Therapeutic Area Head, Bayer Sp. z o.o
ClinicalTrials.gov Identifier:	NCT00471003 History of Changes
Obsolete Identifiers:	NCT00459095
Other Study ID Numbers:	12729, KL0601PL, 13929 - KL0601SI, 12804 - KL0601SK, 14326 - KL0601HR
Study First Received:	May 7, 2007
Last Updated:	January 19, 2010
Health Authority:	Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products; Slovakia: State Institute for Drug Control; Croatia: Agency for Medicinal Product and Medical Devices; Croatia: Ethics Committee; Slovenia: Ethics Committee

Keywords provided by Bayer:

Hypertension

Additional relevant MeSH terms:

Hypertension
Vascular Diseases
Cardiovascular Diseases
Telmisartan
Benzoates
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action

Pharmacologic Actions
Angiotensin-Converting Enzyme Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Antifungal Agents
Anti-Infective Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on February 09, 2012